A 10ª edição do boletim Infectologia Hoje dedica-se a uma reciclagem sobre o diagnóstico e tratamento dos linfomas, abordando especificamente a interface desta patologia com a Infectologia.
:: Versão para impressão
Veja o conteúdo desta edição na íntegra, fazendo o download do arquivo abaixo (PDF):
Infectologia Hoje: ano III - nº 10 - Linfomas: diagnóstico e tratamento [176 KB]
:: Bibliografia de referência
• Apresentação "Linfomas: do diagnóstico ao tratamento" durante sessão da I Conferência Brasileira de Infectologia. Acesse: Projeto Linfoma - Dra. Gisele W. B. Colleoni [3,20 MB]
• ARMITAGE JO. How I treat patients with diffuse large B-cell lymphomas. Blood. 2007;110(1):29-36.
• DAVE SS, WRIGHT G, TAN B et al. Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells. N Engl J Med. 2004; 21:2159-69.
• GRIBBEN JG How I treat indolent lymphoma. Blood. 2007;109(11): 4617-26.
• HANS CP; WEISENBERGER DD; GREINER TC et al. Conformation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood. 2004;103:275–282.
• JAFFE ES, HARRIS NL, STEIN H, et al. World Health Organization Classification of Tumors. Pathology and Genetics. Tumours of Haematopoietic and Lymphoid Tissues. Lyon, France: IARC Press 2001.
• NCCN. National Comprehensive Cancer Network. The complete library of practice guidelines in oncology. Versão 2007. Disponível em https://www.nccn.org.
• SOLAL-CELIGNY P, ROY P, COLOMBAT P et al. Follicular lymphoma international prognostic index. Blood 2004; 104: 1258-65.
• SEHN LH, DONALDSON J, CHHANABHAI M, et al. Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma in British Columbia. J Clin Oncol. 2005;23(22):5027-33.
• SEHN LH, BERRY B, CHHANABHAI M, FITZGERALD C, GILL K, et al. The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuselarge B-cell lymphoma treated with RCHOP. Blood. 2007; 109(5):1857-6.
• SWEETENHAM JW. Diffuse Large B-Cell Lymphoma: Risk Stratification and Management of Relapsed Disease. Hematology Am Soc Hematol Educ Program. 2005:252-259.
• The International Non-Hodgkin’s Lymphoma Prognostic Factors Project. A predictive model for agressive non-Hodgkin’s lymphoma. N Engl J Med. 1993; 392: 987-94.
• VAN OERS MH, KLASA R, MARCUS RE, WOLF M, KIMBY E, GASCOYNE RD, et al. Rituximab maintenance improves clinical outcome of relapsed/resistant follicular non-Hodgkin’s lymphoma, both in patients with and without rituximab during induction: results of a prospective randomized phase III intergroup trial. Blood. 2006;108(10):3295-301.
